Colorectal Cancer

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses maintenance therapy for patients with metastatic colorectal cancer.

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.